Surgical and Animal Core

我们实验室的一个标志是开发了新颖和创新的体内肿瘤模型，使我们能够 治疗药物传递过程中的学习障碍。这只有可能是因为杰出的外科手术 斯蒂尔实验室自1975年成立以来，拥有专业的专业知识和独特的动物设施。此核心 将继续发挥两个主要功能：(I)手术支持，包括新的动物模型 (2)培育和维持小鼠，包括基因工程小鼠(GEM)。 两者对于成功完成所有计划项目赠款(PPG)目标都至关重要。因此，核心C是一个 这个PPG的基石。这一核心将继续发展或改进，并提供复杂的矫形 肿瘤模型-同种异体肿瘤移植(所有四个项目)-以及颅窗(项目1)、肺 窗口(项目2)、肝肿瘤准备(项目2、3)和腹部窗口(项目4)。这些遗嘱 在体内实现分子、细胞、解剖学和功能参数的时间进程监控 脑、结肠、肝、胰腺肿瘤及其转移的原位器官环境。此外, 该核心将在修订后的PPG中显著扩展GEM车型的维护和提供，以便 满足所有4个项目对创业板的需求激增，以研究宿主微环境在应对中的作用 自发性肿瘤的治疗。通过领导COX-7灵知生菌动物的运作 设施。黄博士将继续确保所有实验动物的质量一致，不含 小鼠病毒、病原菌和寄生虫。这将使PPG团队能够执行所有 不使用抗生素的实验程序。这些研究极其困难，成本也更高。 其他地方。目前，在COX-7设施中有26个定义了菌群的基因工程小鼠品系。 根据所有4个项目的需要，还将设计或重新衍生、培育和 在工厂内生产的。经过筛选且没有老鼠病原体的肿瘤将连续传代 在体内，并植入群体内的实验动物体内。体内肿瘤不会传代 超越第五代(F5)，避免肿瘤特性的变化。这确保了对 动物和肿瘤的质量。CORE C将继续提供标准的动物程序，如 控释泵植入、血管放置、术后护理和组织收集。

A hallmark of our laboratory is the development of novel and innovative in vivo tumor models that allow us to study barriers in the delivery of therapeutic agents. This is only possible because of the outstanding surgical expertise and unique animal facility available in the Steele Laboratory since its inception in 1975. This Core wiil continue to serve two major functions: (i) the surgical support, including novel animal model development, and (ii) the breeding and maintenance of mice, including genetically engineered mice (GEM). Both are vital for successful completion of all Program Project Grant (PPG) goals. Thus, Core C is a cornerstone of this PPG. This Core will continue to develop or improve and provide sophisticated orthotopic tumor models - syngeneic tumor grafts (all four Projects) - as well as cranial window (Projects 1), lung window (Project 2), liver tumor preparation (Project 2, 3) and abdominal window (Project 4). These will enable in vivo time-course monitoring of molecular, cellular, anatomical, and functional parameters in the orthotopic organ environment of brain, colon, liver and pancreatic tumors and their metastases. In addition, this Core will significantly expand maintenance and provision of GEM models in this revised PPG in order to meet a surge of GEM demand from all 4 Projects to study the role of the host microenvironment in response to treatment in spontaneous tumors. Through his leadership of the operation of Cox-7 gnotobiotic animal facility. Dr. Huang will continue to ensure that all experimental animals are of uniform quality and free of murine viruses, pathogenic bacteria, and parasites. This will enable the PPG team to carry out all experimental procedures without the use of antibiotics. These studies are extremely difficult and more costly elsewhere. Currently 26 defined-flora genetically engineered mouse lines are available in the Cox-7 facility. Based on the need of all 4 Projects, additional mouse lines will also be engineered or rederived, bred, and produced within the facility. Tumors that are screened and free of mouse pathogens will be serially passaged in vivo and implanted into experimental animals within the colony. In vivo tumors will not be passaged beyond the fifth generation (F5) to avoid changes in tumor characteristics. This assures tight control of the quality of animals and tumors. Core C will continue to provide standard animal procedures such as controlled-release pump implantation, vascular line placement, post-surgical care and tissue collection.